בי.סי.ג'י - BCG

בי.סי.ג'י - BCG
התוויות	For the treatment of superficial transitional cell carcinoma (TCC) of the urinary bladder, regardless of antecedent intravesical treatment superficial TCC comprises the following: carcinoma in situ (CIS), papillary tumors limited to the mucosa (stage Ta), papillary tumors invoiving the lamina propria but not the muscle layer of the bladder (stage T1), or any combination thereof. Immucyst is indicated for treatment and prophylaxis of primary or recurrent carcinoma insitu (CIS) of the urinary bladder and for prophylaxis following trans-urethral resection (TUR) of primary or recurrent stage Ta and/or T1 papilary tumors

דרך מתן

בי.סי.ג'י - BCG
שמות מסחריים	®IMMUCYST


קבוצה פרמקולוגית (ATC)	"OTHER IMMUNOSTIMULANTS"
שם גנרי	"בי.סי.ג'י" (קישור לדף התרופה במאגר משרד הבריאות)
סל הבריאות	לא כלול
התוויות	For the treatment of superficial transitional cell carcinoma (TCC) of the urinary bladder, regardless of antecedent intravesical treatment superficial TCC comprises the following: carcinoma in situ (CIS), papillary tumors limited to the mucosa (stage Ta), papillary tumors invoiving the lamina propria but not the muscle layer of the bladder (stage T1), or any combination thereof. Immucyst is indicated for treatment and prophylaxis of primary or recurrent carcinoma insitu (CIS) of the urinary bladder and for prophylaxis following trans-urethral resection (TUR) of primary or recurrent stage Ta and/or T1 papilary tumors
שם יצרן	SANOFI PASTEUR LTD, CANADA
שם בעל הרישום	MEDICI LTD
עלון לרופא	"עלון לרופא באנגלית"